A. Lung squamous cell carcinoma ENSG00000247675 treatment_outcome_first_course. Kruskal–Wallis, p = 0.016. lncRNA expression across Clinical groups: Progressive Disease (n=10), (Not Applicable) (n=9), Complete Remission/Response (n=71), Partial Remission/Response (n=1), Stable Disease (n=5).

B. Survival probability vs Time (Years). Strata: Low Expression, High Expression. p = 0.00038. Number at risk — Low Expression: 220, 154, 92, 59, 44, 33. High Expression: 221, 165, 106, 69, 50, 40.

C. Breast invasive carcinoma ENSG00000266850 PAM50.mRNA. Kruskal–Wallis, p = 0.00032. lncRNA expression across Clinical groups: Luminal A (n=218), Basal-like (n=70), Luminal B (n=110), HER2-enriched (n=35), Normal-like (n=8).

D. Survival probability vs Time (Years). Strata: Low Expression, High Expression. p < 0.0001. Number at risk — Low Expression: 490, 416, 244, 175, 125, 93. High Expression: 490, 418, 293, 216, 173, 134.

maybe do fisher's test instead
risk group versus non-risk group how many patients are
of each molecular subtype. compare survival models
performance using these variables compared to
lncRNA expression.